The annual World Conference on Lung Cancer (WCLC) has returned on September 11th – 14th, marking the second time the world’s largest event to bring together researchers and physicians in the field of thoracic oncology and lung cancer virtual. The conference is hosted by The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated solely to the study of lung cancer. This is our fifth consecutive year presenting at the conference.

This year, Geneseeq will be presenting a mini oral covering the topic of Detecting Stage I Lung Cancer with High Sensitivity Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell-Free DNA (cfDNA). This is the first time Geneseeq to release data from our DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features) program, demonstrating the promising performance of our liquid biopsy technologies at ultra-high sensitivity and specificity.

Highlights of this study include:

  • The study prospectively designed study with 522 participants including 292 Stage I lung adenocarcinoma patients and 230 healthy controls.
  • By implementing cell-free tumor DNA detection technologies, the results are improved compared to traditional detection methods like low-dose CT scans.
  • A stacked ensemble model with five different machine learning models was established to identify cancer patients from healthy individuals.
  • In total, a sensitivity of 95% and a specificity of 93% were achieved, which outperformed all the previous published studies.

About Geneseeq

Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels to help match patients to optimal treatments, including targeted therapy and immunotherapy. We have 1000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. Our headquarters are located in Canada and China. Our CAP/CLIA-accredited Chinese site is equipped with multiple advanced NGS sequencing platforms and has sequenced 400,000+ clinical samples. For more information, please visit or follow Geneseeq on Linkedin and Twitter.